Coherus Biosciences

The firm is focused exclusively on immuno-oncology, developing combination therapies designed to overcome immune resistance in cancer. Its pipeline includes multiple clinical-stage candidates that target the tumor microenvironment. This specialization is underpinned by its commercial-stage asset LOQTORZI, an FDA-approved treatment for nasopharyngeal carcinoma.

Coherus is a commercial-stage operating biotechnology company, not an investment fund. It manages its own drug development, clinical trials, regulatory approvals, and commercial sales in-house. Capital allocation is directed toward advancing its internal pipeline rather than deploying into external portfolio companies.

LOQTORZI (toripalimab-tpzi) is Coherus's approved immuno-oncology therapy and the only FDA-approved drug for recurrent, advanced or metastatic nasopharyngeal carcinoma. It can be administered in combination with chemotherapy or as a single agent. As the company's core commercial product, LOQTORZI serves as the revenue foundation that supports additional pipeline development.

Coherus advances both commercial and clinical-stage assets. Its pipeline consists of investigational immuno-oncology candidates currently in clinical trials across multiple cancer indications. The company has not publicly segmented its portfolio by Phase I, II, or III designations in a detailed pipeline chart, but its disclosures confirm active clinical-stage programs targeting the tumor microenvironment.

The company's headquarters is located at 333 Twin Dolphin Drive in Redwood City, California, with a second office in Camarillo, California. These two US locations house its commercial, clinical, and administrative functions.